carcinogens were mutagens. This simplistic theory has been largely dominated by the fact that initially a large number of carcinogens were active in the Ames Salmonella mutagenicity assay. The fact that an increasing number of animal carcinogens are negative in the Ames test has led to the suggestion that some carcinogens may act via epigenetic or non-genotoxic mechanisms . Conceivably some carcinogens could be indirect mutagens, for example by interfering with spindle assembly during mitosis leading to chromosomal aberations, by reducing the efficiency of DNA repair mechanisms or by altering the methylation state of DNA. Alternatively, some non-genotoxic carcinogens could mimic the effect of natural signal transduction factors and therefore perturb normal cell growth and differentiation. In this case, rather than acting as initiators of tumourigenesis, such carcinogens may act as tumour promoters by altering the growth or differentiation of a cell that contains an initiating lesion as a result of either a spontaneous event (e.g. DNA replication error) or an environmental mutagen.
There is increasing evidence that the action of some non-genotoxic carcinogens is mediated by receptors. It is well known, for example, that the phorbol ester and potent skin tumour promoter, TPA, can activate protein kinase C (PKC) which is an important intermediate in the signal transduction ~athway between the cell surface and the nucleus. Other data suggests that the carcinogenic action of other non-genotoxic carcinogens such as synthetic oestrogens,4 4 TCDD (2,3,7,8 tetrachloro dibenzo-p-dioxin),5 and peroxisome proliferators (PPs)' (see below) may be mediated by specific intracellular receptors. Intriguingly, the latter examples are all receptors that belong (oestrogens, PPs) or are thought to belong (TCDD) to the superfamily of nuclear hormone receptors (see below). We have used PPs as a valuable model system to gain more insight into the mechanism of action of such non-genotoxic carcinogens.
Peroxisome proliferators and rodent . hepatocarcinogenesis . ' A wide variety of chemicals when administered to rats and mice produce a dramatic increase in both the size and number of peroxisomes. The list includes several hypolipidemic drugs, herbicides, leukotriene antagonists and plasticizers that together are termed peroxisome proliferators (PPS)7-9. Some of the more potent PPs are hypolipidemic drugs (e.g. Wy 14,643) whereas plasticizers such as di-(2-ethyhexyl) phthalate (DEHP) are much weaker. In rats and mice these compounds produce hepatomegaly as a result of both liver hyperplasial iz and the increase in peroxisomal volume. 10,13 The levels of several peroxisomal enzymes, 13,14 as well as members of the microsomal cytochrome P450 IV gene family'5 are elevated 10-30-fold in response to PP administration. These increases are parallelled by induction of their respective mRNAs observed as early as 2 h after PP administration and reflect an increase in transcription. 16--18 The peroxisomal enzymes studied in most detail include acyl CoA oxidase (ACO), bifunctional enzyme (BFE) and thiolase. Together, these enzymes are responsible for the peroxisomal 13-oxidation of long chain fatty acids. ACO is the key enzyme in this pathway since it is both the rate-limiting step and, in addition, produces the hydrogen peroxide that some have implicated in the hepatocarcinogenic process (see below).
The basic mechanism(s) by which the nongenotoxic PPs induce tumours in rats and mice is unknown. Interestingly, the carcinogenic potency of the various PPs differs considerably. For example, 0.1 % Wy-14,643 fed to rats will produce a 100% liver tumour incidence after 60 weeks' 9,20 compared with only about 10% in male rats fed 1.2% DEHP for 2 years. 21 The oxidative stress hypothesis was proposed by Redd y7 to explain how PPs may cause cancer and is based upon a correlation between the ability of a compound to stimulate peroxisome proliferation and induce tumours. It is proposed that hydrogen peroxide, produced by the increase in peroxisomal fatty acid]3-oxidation, results in oxidative stress leading to DNA damage and possibly tumour initiation.~ 7 In support of this model, an approximate doubling in the number of 8-OH-deoxyguanosine lesions is observed in the liver of rats chronically fed a diet containing a potent PP22 and DNA alterations are detectable by the 32P post-labelling assay.23
However, a comparison between the effects of DEHP and Wy-14,643 over a 12-month period indicated that tumours were observed in rats fed Wy-14,643 but not with DEHP, despite the fact that DEHP produced only 25% less peroxisome proliferation than Wy-14,643.2o Therefore, because of the better correlation between the carcinogenicity of DEHP and Wy 14,643 and their mitogenic effects in the liver it has been suggested that PPs could act as tumour promoters.2o,2s. Thus changes in growth and differ- Figure 1 Model of peroxisome proliferator action. Peroxisome proliferators are assumed to enter the cell by diffusion and to either bind directly to the receptor (PPAR) or to perturb lipid metabolism leading to induction of the proximate peroxisome proliferator. PPAR is shown located in the nucleus and is speculated to recognize TGACCT motifs located upstream of target genes such as ACO. The activated receptor would then enhance (e.g. ACO) or repress gene transcription resulting in peroxisome proliferation, and changes in differentiation and growth. It is proposed that some of these events are relevant to the carcinogenic mechanism of peroxisome proliferator action. entiation induced by PPs maybe important in the carcinogenic mechanism rather than the stimulation of peroxisomes per se.
PPAR: a member of the nuclear hormone receptor superfamily
The nuclear hormone receptor superfamily comprises at least 25 mammalian receptors whose ligands include the classical steroid hormones, thyroid hormones, vitamin D3 and retinoic acid. 26--28 Nuclear hormone receptors are intracellular proteins, often localized in the nucleus, that bind their cognate ligand with high affinity and specificity and in addition recognize short DNA motifs generally termed hormone response elements (HRE). Such HREs are usually located upstream of the target genes and behave as transcriptional enhancers.29,3o The binding of the ligand-receptor complex to their cognate HRE can either activate or repress specific gene transcription. 31-33 Nuclear hormone receptors are therefore ligand-dependent transcriptional modulators.
The possibility that the biological mediator of PP action could be a member of the steroid hormone receptor superfamily prompted us to screen a mouse liver cDNA library using a probe derived from the combined sequences of several such receptors. One of the receptors we identified can be activated by a variety of PPs including hypolipidemic drugs and a metabolite, MEHP (mono 2-ethylhexyl phthalate), of the plasticizer DEHP.~ We have termed this receptor PPAR for the Peroxisome Proiferator Activated Receptor. PPAR shares a common primary organization with the other nuclear hormone receptors and contains regions homolgous to both the DNA and ligand binding domain. The concensus DNA binding domain is approximately 70 amino acids in length and folds into a single domain containing two alpha helical regions and a hydrophobic core.34 There is good evidence indicating that amino acids within the first helix (the proximal box) make specific contacts within the major groove of DNA and therefore define target gene specificity.3s-3Ã ctivation of PPAR by peroxisome proliferators A chimeric receptor constructed using the DNA binding domain of the oestrogen (ER-PPAR) receptor and the putative ligand binding domain of PPAR is able to activate an oestrogenresponsive gene in the presence of PPs.~ When ER-PPAR was tested using several different PPs a good correlation was observed between their ability to activate ER-PPAR and their potency either as PPs or as rat liver carcinogens. For example, Wy 14,643 was more potent in the chimeric receptor assay than MEHP the primary DEHP metabolite. These data suggest that PPAR could mediate the biological effects of PPs. Further support comes from a study of the tissue specific expression of PPAR that compares well with the tissue specific induction of ACO by pps. 6.38 . Given the diversity of PPs that activate PPAR it is interesting to speculate whether they bind to PPAR directly or modulate its activity through some indirect mechanism. One possibility for an indirect mechanism of action would be if PPs cause a perturbation in lipid metabolism that induces the natural PPAR ligand. Alternatively, PPs could cause changes in the phosphorylation of signal transduction proteins, perhaps including PPAR, as has recently been suggested to explain how dopamine activates the COUP nuclear hormone receptor.39 It is therefore interesting to note that experiments using labelled nafenopin have so far failed to demonstrate any direct binding.~ This could, however, be due to several factors such as the presumed low affinity of nafenopin for PPAR (as judged from the dose response curves), from the low level of PPAR expression, or because of the presence of additional PP binding proteins such as the heat shock related protein PPBP.4° Interestingly, structure activity comparisons obtained in other studies 41-43 provide supportive evidence for direct interaction between PPs and some macromolecular mediating protein, possibly PPAR.
Since natural factors such as a high fat diet4a,as 
proliferator action
In order to define a link between the activation of PPAR and the phenomena of peroxisome proliferation and hepatocarcinogenesis it is important to determine whether PPAR is directly responsible for the transcriptional activation of PP responsive genes. Of special interest is the peroxisomal f3oxidation enzyme ACO since this enzyme is responsible for the production of hydrogen peroxide and is therefore tentatively linked with cancer (see above). A comparison of primary amino acid sequence reveals complete identity within the proximal box of the DNA binding domain of PPAR and other nuclear hormone receptors that bind to a DNA sequence related to TGACCT or TGAACT.&dquo; [34] [35] [36] [37] 48, 49 We therefore predicted that PPAR recognizes a similar motif} Examination of the promoter region of the rat ACO gene 50 reveals several such motifs and we now have evidence that a sequence that contains a TGACCT motif positioned approximately 570 nucleotides upstream of the transcription initiation start site binds PPAR and is important in mediating the response to PPS.51 Other studies support the conclusion that this region of ACO is important in confering responsiveness to PPs.s2
These data therefore indicate that PPAR is responsible for mediating the induction of the key marker of the PP response. Regulation of ACO expression by PPAR could explain the carcinogenic effects of PPs (see above). Alternatively, tumour formation could result from important changes in cellular growth and differentiation. 53 Therefore PPAR may alter the expression of key genes relevant to growth and differentiation such as oncogenes5 growth factors or their receptors.s6 The identification of the carcinogenic mechanism by which PPs and other non-genotoxic carcinogens such as 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD), influence tumourigenesis is an important area of research that should yield valuable insights into the mechanisms of non-genotoxic carcinogenesis.
Species comparisons
It is intriguing that the phenomena of peroxisome proliferation, is observed in species such as mouse, rat and hamster but not in guinea pig, and monkey. 57-59 Importantly, no effects were seen in humans 60,61 or when using human hepatocyte cultures. The basis for the species differences in response to PPs is unlikely to be due to differences in metabolism or pharmacokinetics 57 and appears to reflect differences in the way that hepatocytes respond to the PP stimulus. If peroxisome proliferation is mediated by PPAR then such species differences could reflect either variation in PPAR or in the gene networks regulated by PPAR. We are therefore examining both the level of PPAR expression as well as the activity of PPAR in response to PP amongst species since this has important consequences in assessing the hazard PPs pose to man. Clearly the data so far supports a model where PPAR is the mediator of PP action (Figure 1 ). By analogy with the mechanism of action of other nuclear hormone receptors PPAR would be activated by the binding of PP, recognize specific DNA sequence motifs located upstream of PP target genes (PPRE) and activate specific gene transcription. Such target genes would include those of the J3-oxidation enzymes and P450 IVAb ut could also include genes important in the hyperplastic and carcinogenic response. It will be important to determine whether all of the effects of PPs are receptor mediated. If they are then learning more about the role and function of PPARpresents an exciting and unique opportunity to understand more about the role of PPs in peroxisome proliferation and cancer. Current models used in risk assessment generally assume that carcinogens are mutagens and that a single mutation (or optimistically two) in a single cell is sufficient to produce a tumour. The linear multistage model therefore extrapolates data from animal bioassays to determine no effect levels (NOEL) with an arbitrary safety factor such as 100 to determine acceptable levels for human exposure.62 Such models have been suggested to be unrealistically over cautious when applied to chemicals whose action may be receptor mediated. 63 It is possible, for example, to measure threshold levels of receptor activation below which no increases are observed. Moreover such models could be tested experimentally by establishing a lifetime rodent bioassay using a concentration of chemical that produced, for example, only 1 % receptor activation. Such a small amount of activation is unlikely to be sufficient to trigger tumourigenesis since there will always be background noise in any biological system. A further concept of a receptor model for risk assessment is that the receptor acts as a trigger for the biological effects of the chemical and therefore its abundance is an important factor. Species or tissues that contain reduced amounts of receptor would therefore be less sensitive to the effects of the chemical.
It is clear that the mechanism of action of agents such as PPs, TCDD and TPA is different from that of genotoxic chemicals such as di-ethyl nitrosamine (DEN). It is therefore important that we use present and future knowledge to update the models used to define safe exposure levels for man.
Stephen Green Imperial Chemical Industries, PLC, Central Toxicology Laboratory, Cell and Molecular Biology Section, Alderley Park, Macclesfield, Cheshire A Clinical Scientist's View of Preclinical Drug Testing Requirements A game with which journal editors frequently amuse themselves is to take a topic on which the scientific community is hopelessly divided and invite two authors of entirely different backgrounds to submit their views on the matter. The rules of the game do not permit a consensus view to be arrived at, and the hoped for result is two polarized opinions expressed in such a robust and irreconcilable manner that, after a suitable interval, two more players can again be invited to solve the insoluble.
On how many occasions has the topic of the relevance of preclinical drug testing been debated? The only agreement which has ever been reached is that before a drug is given to man, some preliminary assessment in lower species is probably required, but every detail of this assessment has been disputed. My role in this
